2024 European Society for Medical Oncology (ESMO) Congress
Clinical Candidates
ADG126
Results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody) in combo with pembrolizumab (Pembro) in patients (Pts) with metastatic microsatellite-stable (MSS) colorectal cancer (CRC)
ADG126 | ASCO-GI 2024
Interim Results of a Phase 1b/2 Study of ADG126 (a Masked anti-CTLA-4 SAFEbody®) Monotherapy and in Combination with Toripalimab (an anti-PD-1 Antibody) in Patients (pts) with Advanced / Metastatic Solid Tumors
ADG126-1001 | AACR 2023
Initial Results of a Phase 1b/2 Study of ADG126 (a Masked Anti-CTLA-4 SAFEbody®) in Combination with Pembrolizumab (an Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors
ADG126-P001 | AACR 2023
Results Demonstrate Highly Differentiated Safety and PK Profile of ADG126, a Masked anti-CTLA-4 SAFEbody® in Patients with Advanced Solid Tumors Phase 1
ADG126 | ESMO 2022
A Novel Anti-CTLA-4 Checkpoint Inhibitor Prodrug to Address On-target Off-tumor Toxicity for Cancer Immunotherapy
ADG126 | AACR 2021
ADG106
Assessment of Biomarker Kinetics for ADG106 (anti-CD137 Agonist) as Monotherapy or Combined with Toripalimab
ADG106 | ESMO IO 2021
Identification of a predictive biomarker and two pharmacodynamic biomarkers to ADG106 treatment, a novel anti-CD137 agonist antibody, in phase I clinical trials
ADG106 | ASCO 2021
Phase 1, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma
ADG106 | ASCO 2020
A Safe and Potent Agonist ADG106 Targeting a Unique Epitope of CD137 with Novel Mechanism of Actions
ADG106 | EORTC-NCI-AACR 2019
Preclinical Candidates
ADG153
Tumor-targeted CD28 bispecific POWERbody
Tumor-targeted CD28 bispecific POWERbodyTM for safe and synergistic T cell-mediated immunotherapy
CD28 bispecific POWERbody | AACR 2022